Clinical Trials
HMR-1001
HMR-1001 is a Phase 1 FDA approved clinical trial that is closed to enrollment and inactive as of January 2020. HMR-1001 evaluated 17 eyes of 17 subjects with advanced dry AMD and geographic atrophy who received a single intravitreal dose of HMR59. Information on HMR-1001 is available here:
HMR-1002
HMR-1002 is a Phase 1 FDA approved trial for the treatment of 25 subjects diagnosed with new onset wet AMD who have never received treatment in the affected eye. HMR-1002 enrolled subjects at Ophthalmic Consultants of Boston and Vitreo-Retinal Associates in Worcester, MA. All patients who met enrollment criteria were treated with a single intravitreal injection of an anti-VEGF medication followed 7 days later by an intravitreal injection of HMR59. Patients were followed monthly and treated with anti-VEGF injections as needed through month 12 followed by a month 24 visit to evaluate long-term safety. Information on HMR-1002 is available here: